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Diabetic nephropathy: Recent insights into the pathophysiol-
ogy and the progression of diabetic nephropathy. Diabetes has
become the single most frequent comorbid condition in patients
admitted for renal replacement therapy. This is the result of a
greater prevalence of type 2 diabetes and better survival of di-
abetic patients. Progress has been made in pinpointing the pre-
disposition to diabetes on metabolic abnormalities of muscle
mitochondrial metabolism, but the long sought genes predis-
posing to diabetes and to diabetic nephropathy have not yet
been identified. Of great concern are experimental studies doc-
umenting that maternal hyperglycemia causes nephron under-
dosing in the offspring.
Relevant to pathogenesis and treatment of diabetic
nephropathy are, among others, recent insights that hyper-
glycemia sensitizes target organs to blood pressure–induced
damage, and that local renin-angiotensin systems play an im-
portant role in genesis and progression of diabetic nephropathy.
Diabetic nephropathy has become the single most fre-
quent condition causing end-stage renal disease, and it is
fully justified to call it “a medical catastrophe of world-
wide dimension” [1]. Currently, 49% of incident patients
in Heidelberg admitted for renal replacement therapy
suffer from diabetes mellitus, 6% of type 1 and 94% of
type 2 [2]. Because the major epidemiologic problem is
type 2 diabetes, this text emphasises this type of diabetes.
The presence of diabetes is not only associated with
enormous human suffering, but also with an abysmal life
expectancy. In a prospective study in Germany, we found
that five-year survival was less than 10% in the elderly
type 2 diabetics, and no more than 40% in the younger
type 1 diabetic patients [3]. The high proportion of type 2
diabetes is grotesque in view of the fact that two decades
ago it had been postulated that type 2 diabetes was a be-
nign condition with respect to renal function [4]. This view
reflected mainly a biostatistical artifact, since at that time
the life expectancy of elderly type 2 diabetics was rather
poor. When one calculates the cumulative prevalence of
Key words: diabetic nephropathy, microalbuminuria, thrifty genotype,
nephron number, hypertension, renin-angiotensin.
C© 2005 by the International Society of Nephrology
proteinuria or of renal failure in type 2 diabetics as a func-
tion of the years survived, however, the renal risk is either
identical [5] or even higher [6] in type 1 compared to type
2 diabetes.
The renal complications of diabetes have become one
of the greatest challenges of nephrology of today [7].
There is no doubt that in all Western societies the fre-
quency of type 2 diabetes increases dramatically, par-
ticularly so in the developing world. Thus, ever more
individuals are exposed to the risk of ultimately devel-
oping diabetic nephropathy [8]. It is therefore appropri-
ate to briefly discuss the factors underlying this modern
“epidemic” of diabetes.
SOME RECENT CONCEPTS CONCERNING TYPE
2 DIABETES
It has been argued that the genetic predisposition to di-
abetes that is so frequent in Western societies, and even
more so in minorities, reflects the fact that in the dis-
tant past insulin resistance conferred a survival advan-
tage (“thrifty genotype” hypothesis) [9]. This concept
finds support in archeologic findings [10] and in the fol-
lowing recent observation. In Australian aboriginals, di-
abetes and diabetic nephropathy develop with excessive
frequency [11, 12]. When diabetic aboriginals returned to
the lifestyle of their ancestors as hunters and gatherers,
hyperglycemia and hyperlipidemia disappeared within
weeks [13].
Using innovative techniques, Petersen [14] recently
discovered a metabolic defect in nondiabetic individu-
als at high risk of developing diabetes. In these indi-
viduals, insulin resistance was associated with reduced
ATP synthesis in muscle and with increased myocellu-
lar triglyceride content, pointing to muscle mitochondria
as a primary culprit. Going beyond the concept of the
thrifty gene, interesting recent work with Caenorhabditis
elegans and drosophila showed that the life expectancy
is increased by nutrient deficiency and by diminished
insulin action [15, 16]. Reduced glucose flux and lower
mitochondrial oxidation are associated with reduced for-
mation of reactive oxidant species (ROS), reduced ROS
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dependent protein modification, and reduced nitrotyro-
sine and carboxymethyllysine production [17]. It is of in-
terest that transfection with glyoxylase, which reduces
the concentration of methylglyoxal and of advanced gly-
cation end product (AGE), prolongs the lifespan. These
findings led to the hypothesis that diminished mitochon-
drial oxidation of glucose-derived metabolites confers a
survival benefit under conditions of low nutrient supply,
but causes diabetes, and shortens survival once abundant
nutrient supply leads to hyperglycemia and high glucose
delivery to non–insulin-dependent tissues [18].
THE RENAL RISK OF DIABETES: BEYOND THE
CURRENT GENERATION?
Brenner proposed the hypothesis [19] that a dimin-
ished endowment with nephrons increases the risk of hy-
pertension and of renal disease. In this context, it is of
interest that diabetes in pregnant rats diminishes the kid-
ney weight and the number of glomeruli [20]. This finding
can be imitated by hyperglycemia of the mother at a crit-
ical time window when the fetal metanephrosis develops.
It could be shown that reduced free insulin like growth
factor (IGF) (e.g., in pups of pregnant rats overexpress-
ing IGF binding protein or conditional overexpression of
IGF bp in transgenic pups affected the nephron number).
The number could also be modulated varying the avail-
ability of free IGF in the kidney anlage by transfecting
IGF/IGF2R antisense oligo nucleotides [21]. Thus, apart
from low birth weight or medications [22], hyperglycemia
in the mother may increase the risk of hypertension and of
renal disease in the offspring—a perspective that is fright-
ening given the current epidemic in ever-younger individ-
uals of type 2 diabetes, including pregnancy-associated
diabetes.
MICROALBUMINURIA
The pioneer work of Danish diabetologists has doc-
umented that trace amounts of albumin in the urine
predict both a high renal and cardiovascular risk. It is
possible that immunoreactive albumin in the urine is just
the tip of an iceberg, and that non-immunoreactive al-
bumin or albumin degradation products assessed by pro-
teomic techniques will in the future even be earlier and
more sensitive indicators of renal risk [23]. What has
emerged recently is that the definition of microalbumin-
uria of 30 to 300 mg/day albumin excretion may be too lib-
eral as well. Rachmani [24] showed (Table 1) that in type
2 diabetic patients the renal and cardiovascular risk in-
creased progressively with albumin excretion rates within
the normal range. The natural history of microalbumin-
uria in type 2 diabetic patients has recently been more
fully documented in the UKPDS Study [25]. The risk to
progress from normo- to microalbuminuria, from micro-
Table 1. Progressive increase of renal and cardiovascular risk for
rates of albumin excretion within the normal range in patients with
type 2 diabetics
Relative risk
Progression to microalbuminuria CV end point
0 to 10 1 1
10 to 20 2.34 1.9
20 to 30 12.4 9.8
Reprinted from Rachmani et al, Diab Res 49:187, 2000.
to macroalbuminuria, or from macroalbuminuria to renal
failure is 2% to 3% so that, if one can extrapolate, approx-
imately 40% of type 2 diabetics will eventually develop
nephropathy if they survive sufficiently long. What is par-
ticularly remarkable is the fact that the annual death rate,
to a large extent from cardiovascular causes, increases
dramatically from 0.7% in a stage of normoalbuminuria
to 12.1% in the stage of increased serum creatinine so
that death from cardiovascular causes is more likely than
the development of end-stage renal disease.
HYPERGLYCEMIA SENSITIZES TARGET
ORGANS TOWARD THE DELETERIOUS
EFFECTS OF BLOOD PRESSURE
One of the major breakthroughs in diabetology in the
past two decades has been the recognition that lowering
blood pressure confers benefit that is comparable to, and
even greater than, the benefit derived from control of
hyperglycemia. To quote C.E. Mogensen [26] “not only
is antihypertensive treatment more effective than tight
blood glucose control, the beneficial results also come
sooner.” In this context, the question arises whether dia-
betic patients are more sensitive to blood pressure values
even within the range of normal tension.
In type 2 diabetes, blood pressure as one facet of the
metabolic syndrome precedes the onset of diabetes by
years or decades. Keller et al [27] examined patients with
newly diagnosed type 2 diabetes and found that 60% had
blood pressure values by ambulatory blood pressure mea-
surements exceeding the then accepted limit of normal,
and no less than 79% were nondippers (<15%). The lat-
ter observation is not pedestrian since Lurbe [28] noted
that in type 1 diabetes an insufficient decline of night time
blood pressure preceded the onset of microalbuminuria.
Furthermore, it is well known that blood pressure lower-
ing, per se, independent of the antihypertensive agent
use, retards onset and progression of renal disease in
type 2 diabetes [29]. This led to the hypothesis that di-
abetes sensitizes the vascular system to the injurious ef-
fects of blood pressure. Presumably for this reason we
recently noted marked renal lesions in an obese hyper-
tensive type 2 diabetes model that were far more pro-
nounced than the lesions in normotensive type 1 diabetes
models, such as streptozotocin [30, 31], or the almost
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absent lesions in the hyperglycemic normotensive type
2 Goto Kakizaki rat. Janssen provided the proof that
superimposition of DOCA salt hypertension provoked
proteinuria and glomerulosclerosis in the normotensive
hyperglycemic Goto Kakizaki rat [32]. He proposed the
hypothesis that hyperglycemia, possibly by producing re-
active oxygen species and AGE, sensitizes endothelial
and other cells to the barotrauma of blood pressure. This
effect is presumably amplified by additional pathologies.
The microcirculation in retina, skin, glomerulus is ex-
posed to a higher blood pressure load because of impaired
autoregulation resulting from vasodilatation, in the case
of the kidney, of the afferent preglomerular arterioles.
Furthermore, the above-mentioned attenuated decrease
of night time blood pressure leads to underestimation of
the blood pressure load with which target organs are con-
fronted. Finally, because of aortic stiffening in diabetes,
blood pressure values in central arteries (e.g., aorta and
renal artery) are higher than blood pressure values mea-
sured in the brachial artery—again causing underestima-
tion of the blood pressure burden. The famous statement
is therefore fully justified: “There is no such a thing as a
normotensive diabetic.”
THE IMPORTANCE OF LOCAL RENIN
ANGIOTENSIN SYSTEMS IN DIABETES
In the past it appeared paradoxical that diabetes as a
low renin state with low PRA [33] is uniquely respon-
sive to pharmacologic blockade of the renin-angiotensin
system (RAS). Today, it is well appreciated that local
RAS exist [34], and are activated in diabetes (e.g., in the
proximal tubular epithelial cells [35], in mesangial cells
[36], and in podocytes [37]). The latter interestingly pro-
duce angiotensin II (Ang II) and exhibit AT1 receptors.
This may explain why in animal experiments nephrin ex-
pression was diminished in diabetes and normalized af-
ter administration of irbesartan or enalapril [38]. In a
prospective biopsy-controlled study, nephrin expression
was lower by 62% in placebo-treated type 2 diabetic pa-
tients, yet was not different from controls in diabetic pa-
tients treated with perindopril. Furthermore, a significant
correlation was found between proteinuria and nephrin
expression [39].
The importance of local RAS for renal hemodynam-
ics has been documented by Price [40], who showed
that despite lower PRA, after administration of the an-
giotensin receptor blocker (ARB) irbesartan, the incre-
ment in renal plasma flow was significantly greater in type
2 diabetics compared to matched controls. This effect is
demonstrable, however, only in the presence of hyper-
glycemia [41].
The important role of local RAS may explain that the
dose response curves for blood pressure lowering and
lowering of urinary protein excretion respectively are
different, higher doses being necessary for maximal uri-
nary protein lowering in experimental animals [42] and
in humans [42]. It is of interest that maximal blood pres-
sure lowering doses of enalaprilat [43] fail to lower in-
terstitial Ang II concentration. It may well be that huge
doses of ACE inhibitors or angiotensin receptor block-
ers are needed for maximally achievable blockade of the
intrarenal RAS.
Blockade of the mineralocorticoid receptor [44] fur-
ther lowers albuminuria despite no further decline in
blood pressure. Further complexity is introduced by the
recognition that aldosterone plays an independent role
in promoting progression of renal disease [45]. A size-
able proportion of patients on ACE inhibitors or ARB
develop aldosterone escape (i.e., a secondary increase
of serum and/or urinary aldosterone despite continuing
RAS blockade). It has recently been shown [46] that in
such patients, additional blockade of the mineralocorti-
coid receptor by spironolactone or by eplerenone further
confers proteinuria.
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